The same property of thalidomide that caused birth defects when it was given to pregnant women—the inhibition of blood vessel formation (anti-angiogenesis)—has led to an interest in thalidomide's therapeutic utility in ...
Jun 10, 2022
0
83
Cancer starts when cells start dividing uncontrollably. Scientists have known that taking aspirin can help protect against the development of colorectal cancer—cancer afflicting the colon or rectum—but the exact reason ...
Jun 10, 2022
0
904
A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers are vulnerable to the ...
Jun 9, 2022
0
64
Despite the availability of highly efficacious vaccines, SARS-CoV-2 still causes serious medical complications. The lack of an effective drug treatment for hospitalized patients with severe COVID-19 has contributed to the ...
Jun 9, 2022
0
42
In a prospective phase II study that involved patients with mismatch repair–deficient locally advanced rectal cancer, treatment with neoadjuvant single-agent, PD1 inhibitor dostarlimab resulted in a clinical complete response—as ...
Jun 9, 2022
0
72
Scientists have, for the first time, revealed at the atomic level the structure of a protein that carries one of the body's most important neurotransmitters into neurons.
Jun 8, 2022
0
61
Leukemia starts in cells that would normally develop into different types of blood cells. About 61,000 people in the U.S. are diagnosed each year, and depending on the type of leukemia and the age of the patient, five-year ...
Jun 8, 2022
0
27
There are racial and socioeconomic inequalities in the prescribing of oral anticoagulants to reduce stroke risk in people with atrial fibrillation, according to a new study conducted in the UK and publishing June 7 in the ...
Jun 7, 2022
0
36
For the first time, a drug targeting a protein that drives breast cancer growth has been shown to work against tumors with very low levels of the protein.
Jun 5, 2022
0
32
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) ...
Jun 3, 2022
0
35
